Kornimate/medical-research-clean huggingface dataset:
statistically analysis of carpal tunnel syndrome diagnosis

Conditions: Carpal Tunnel Syndrome; Diagnosis

Summary: trap neuropathies; they are compression neuropathies that occur as a result of peripheral nerves being compressed for various reasons along their anatomical paths. although each nerve has areas suitable for anatomical entrapment, compression can occur at any point along the nerve. carpal tunnel syndrome (cts) is the most common entrapment neuropathy caused by compression of the median nerve at the wrist level. its prevalence in the general population is 2.5-11%. although the majority of cases are idiopathic, it may also occur secondary to pathologies such as pregnancy, diabetes mellitus, thyroid dysfunction, arthritis, wrist fractures and acromegaly or occupation. the diagnosis of cts is made clinically, but the best method for definitive diagnosis is electrophysiological examination. some anthropometric measurements that may be associated with cts were made and their effect on the risk of cts was investigated. in a study conducted by sabry et al. in 2009, it was reported that there may be a relationship between bmi, wrist ratio (ratio of wrist depth to width) and wrist-palm ratio (ratio of wrist depth to palm length) and cts risk. in a study by lim et al. in 2008, it was reported that the critical value for wrist ratio was 0.70 and above. however, there were no studies reporting how many percent predictors of anthropometric measurements according to the severity of cts.

the study was planned as a quantitative research. socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, visual analog scale scale, emg findings will be evaluated by hand dynamometer. trybus et al. considering the study they conducted in patients with cts in which they examined hand anthropometric measurements in cts, it was planned to include 100 patients in the study with a power range of 80% and an effect width of 0.05.

Eligibility criteria:
inclusion criteria: * admitted to outpatient clinics with symptoms of cts * findings of cts in physical examination * cts diagnosis was confirmed by nerve conduction study * kts grade mild or moderate * he has not received physical therapy for this reason in the previous 1 year * no steroid injection and no treatment for neuropathic pain (pregabalin, gabapentin, etc.) exclusion criteria: * - those under the age of 18 those with a history of previous surgery or fracture of the affected hand and wrist those with diabetes mellitus, chronic kidney failure, gout, rheumatoid arthritis, thyroid diseases * pregnant those with polyneuropathy, radiculopathy, plexopathy, thoracic outlet syndrome

Keywords: carpal tunnell syndrome anthpometric
the effect of terlipressin on intesitnal function in septic shock patients

Conditions: Terlipressin; Septic Shock

Summary: terlipressin becomes a vasopressin for septic shock. but some studies found it may lead to severe intesitnal complications such as intestinal ischemia. the investigators study was designed to find the effect of terlipressin on intestinal function in septic shock patients.


Eligibility criteria:
inclusion criteria: * septic shock exclusion criteria: * shock due to other reasons * diagnosited intesitinal ischemia
a study to evaluate the effects of mk-0249 and an alzheimer's disease medication on cognitive function in adults with alzheimer's disease (mk-0249-023)

Conditions: Alzheimer's Disease; Dementia

Summary: this study will evaluate acute symptomatic improvements in cognitive performance in healthy elderly participants with mild-to-moderate alzheimer's disease. a four-week pilot study will first evaluate the cogstate computerized cognitive battery in participants who are not receiving treatment. after completion of the pilot study, participants will be randomized to receive placebo, donepezil 5 mg, mk-0249 7.5 mg, and mk-0249 25 mg. after each drug administration the participants will be given the cogstate computerized cognitive battery to assess cognitive performance. the primary hypotheses are that cognitive performance in participants with alzheimer's disease, or in healthy participants, is improved by the administration of a single oral 5 mg dose of donepezil as compared to placebo.


Eligibility criteria:
inclusion criteria: patient specific: * female is not of reproductive potential * male who has a female partner(s) of child bearing potential, agrees to use acceptable method of contraception during the study * has at least 10 years of education or work history * has been a nonsmoker or has not used nicotine for at least 6 months * has a diagnosis of mild-to-moderate alzheimer's disease * has a reliable caregiver who consents to accompany the patient to all clinic visits, provide information to the study staff, and return for follow-up visits and procedures healthy elderly volunteer specific: * is in good general health * has no clinically significant abnormality on electrocardiogram (ecg) exclusion criteria: participant specific: * has a history of a neurological disorder other than alzheimer's disease * is living in a nursing home * has a history of stroke * has a history of psychotic disorder, an active major depressive disorder, or history of schizophrenia * has a history of a sleep disorder * has a history of a cardiovascular disorder * has a history of malignancy * is participating or has participated in a study with an investigational compound, device, or vaccine for alzheimer's disease * consumes greater than 6 servings of caffeine (coffee, tea or cola etc.) per day * consumes greater than 3 alcoholic beverages per day * has had major surgery, donated or loss blood in past 8 weeks healthy elderly volunteer specific: * is mentally or legally incapacitated, has significant emotional problems, or has a history of a psychiatric disorder over the last 5-10 years
cardiovascular, renal and metabolic profile in patients with acute myocardial infarction (ren-acs)

Conditions: Hypertension, Renovascular; Renal Artery Stenosis; Myocardial Infarction

Summary: aims * assessment of renal artery stenosis incidence in consecutive ami patients included in the romanian national programme of primary percutaneous revascularisation; * generating a cardio-renal-metabolic profile in patients with renal atherosclerotic disease; * creating a local registry (based on european cards percutaneous interventional registries) which also includes renal, metabolic and vascular data; * reporting long-term follow-up data on major cardiac adverse events (mace) in the study group.

gathered data: * descriptive general demographic data; * previous pathologies (ischemic heart disease, peripheral arterial disease, stroke, heart failure, previous percutaneous coronary interventions, coronary artery bypass grafting - cabg, known renal disease), cardiovascular risk factors (age, weight, height, abdominal perimeter, body mass index, smoking, sedentariness, diabetes, hypertension, dyslipidaemia); * routine biological data and specific non-genetic biomarkers; * information regarding primary pci (less than 12 hours of ischemic symptoms): coronarographic details, type of used stent, periprocedural specific complications, final timi - thrombolysis in myocardial infarction - flow); * echocardiography at admission (lvef); * metabolic data (obtained from body composition monitoring) - body water, body fat tissue; * renal arteries angiographic details (two independent operators evaluate stenosis based on a predefined scale); * renal dimensions; * measurement of arterial stiffness through sphigmocore pulsed-wave-velocity (24 hrs post-procedural, 2 velocities: carotid - femoral and carotid - radial); * heart rate variability; * in-hospital and one month follow-up mace;

Eligibility criteria:
inclusion criteria: * adults with ami (\<12h) diagnostic confirmed; * included in the romanian national programme of primary percutaneous revascularisation (for who the guidelines recommend primary pci); exclusion criteria: * none

Keywords: acute myocardial infarction renal artery stenosis
a study to evaluate the mass balance absorption and ame of vbr

Conditions: Chronic Hepatitis B

Summary: this phase 1 study will determine the mass balance recovery, absorption, metabolism, and excretion of \[14c\] vebicorvir in healthy male subjects


Eligibility criteria:
* consent * male between 18 and 55 years of age (inclusive) at the time of screening * body mass index (bmi) between ≥18.0 kg/m2 and ≤32.0 kg/m2 at screening; body weight between ≥55.0 kg and ≤100.0 kg at screening * considered to be in good health by the investigator exclusion criteria: * history or presence of any condition (e.g., chronic diarrhea) or prior surgery (e.g., gastric bypass) * clinically significant abnormal medical history * history of cancer that has not been in full remission for \>5 years * acute illness within 14 days prior to study drug administration

Keywords: chb hbv hepatitis b
a study of vilazodone in pediatric patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of mdd in pediatric outpatients (7-17 years).


Eligibility criteria:
inclusion criteria: * male or female outpatients betw een 7-17 years of age * primary diagnosis of major depressive disorder (mdd) * children's depression rating scale-revised (cdrs-r) score of 40 or greater * clinical global impressions-severity (cgi-s) score of 4 or greater exclusion criteria: * current (past 3 months) principal diagnostic and statistical manual of mental disorders, fourth edition, text revision based diagnosis of an axis i disorder other than mdd that is the primary focus of treatment (de novo patients only) * history of suicidal behavior, or requires precaution against suicide * not generally healthy medical condition * seizure disorder
neoadjuvant therapy with herceptin and taxol for breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine the effectiveness and safety of administering herceptin in combination with taxol (paclitaxel) in the treatment of women with her2-positive, early stage breast cancer prior to surgery.

patients will receive herceptin intravenously once weekly for 12 weeks, and taxol intravenously every 3 weeks (week 1, week 4, week 7 and week 10). after 12 weeks of treatment, breast surgery will be performed (either a lumpectomy or a mastectomy). once patients have recovered from the surgery, they will receive adriamycin and cytoxan every 3 weeks for 4 cycles (12 weeks total). after herceptin and taxol therapy, tumor assessment will be performed along with an echocardiogram and mammogram. at the time of surgery, re-assessment of the tumor will be done. blood work will be performed on day one of each chemotherapy cycle.

Eligibility criteria:
inclusion criteria: * patients must have stage ii or iii histologically diagnosed breast cancer * primary invasive breast cancers that overexpress the her2/neu oncogene * age older than 18 years * eastern cooperative oncology group (ecog) performance status of \< 1 * white blood cell (wbc) \> 4000/mm3 * platelet count \> 100,000/mm3 * bilirubin \< 1 x upper limit of normal (uln) * sgot \< 1 x uln * creatinine \< 1.5mg/dl * normal cardiac function and electrocardiogram (ekg) showing absence of ischemic changes or ventricular hypertrophy exclusion criteria: * excisional biopsy, sentinel node dissection or axillary node dissection. * prior history of breast cancer unless: diagnosed at least 2 years ago, present cancer is not in a previously irradiated breast, no prior therapy with anthracycline or taxane, no prior high-dose chemotherapy with stem cell or bone marrow transplant. * pregnant or breast-feeding women * uncontrolled infection * active or severe cardiovascular or pulmonary disease * peripheral neuropathy of any etiology that exceeds grade 1 * prior history of malignancy treated without curative intent * uncontrolled diabetes

Keywords: breast cancer early stage breast cancer her2-positive her2-positive breast cancer herceptin taxol stage ii breast cancer stage iii breast cancer
evaluating the neurobiological basis of traumatic dissociation in women with histories of abuse and neglect

Conditions: Posttraumatic Stress Disorders; Dissociative Identity Disorder

Summary: this study aims to evaluate the neurobiological basis of traumatic dissociation in a cross-diagnostic sample of women who have histories of childhood abuse and neglect.

dissociative symptoms commonly are associated with exposure to traumatic stress. preliminary evidence from functional magnetic resonance imaging-based analysis (fmri) of neural activation during dissociative symptom provocation in patients with ptsd or did has implicated certain key structures involved in the generation of dissociative symptoms. given the presumed region-to-region neural interplay implicit within this model, the investigators believe the use of intrinsic functional connectivity mri (fcmri) represents a valuable next line of investigation into the neurobiology of traumatic dissociation. the investigators also believe that a genetic approach holds promise as another converging line of inquiry into our understanding of traumatic dissociation. to evaluate the neurobiological basis of traumatic dissociation, this study will recruit patients with ptsd or did, and recruit matched controls to identify neurobiological correlates of traumatic dissociation.the study will compare the phenomenology of traumatic dissociation in patients with different ptsd subtypes and did using standardized measures to look at the neurological and genetic correlates. this study will also include a follow up visit that includes neuroimaging and genetic assessments.

Eligibility criteria:
inclusion criteria: * female * clinical diagnosis of ptsd or did and history of childhood abuse, or healthy controls * age between 18 and 89 * legal and mental competency of the patient exclusion criteria: * male * under 18 or over 89 * legal or mental incompetence * delirium secondary to medical illness * ptsd or did due to general medical or neurological illness * history of neurological conditions that may cause significant psychiatric symptomatology (e.g., dementia) * any contraindication to mr scans, including claustrophobia, pregnancy, metal implants, etc. * current alcohol or substance dependence or abuse (within the last month) * a history of schizophrenia or other psychotic disorder * history of head injury or loss of consciousness for longer than 5 min (including concussion)

Keywords: neurobiology ptsd did
effects of combined cognitive rehabilitation in copd patients

Conditions: COPD

Summary: this study was to examine the effect of endurance training combined with cognitive training in patients with copd. the intervention group underwent cognitive training added to endurance training and the control group underwent only endurance training.

pulmonary rehabilitation is an essential part of the management of copd. although various methods and therapies of pr have been used in copd patients. furthermore, the cognitive training has been performed people with mild cognitive impairments. therefore, the combination of endurance training and cognitive tarining could be another alternative to improve the exercise tolerance and cognitive function in patients with copd. it may also be useful for clinicians interested in designing new rehabilitation therapies. the aim of the study was to analyze the effect of ct combined with et on exercise tolerance and cognitive functions in copd patient.

Eligibility criteria:
inclusion criteria: * clinically stable copd diagnosed by pulmonary function testing (2) absence of heart diseases, severe psychiatric, neurologic or musculoskeletal conditions and /or instable cardiovascular diseases. (3) absence of medication influencing cognition (4) without history of brain injury, history of stroke or history of alcoholism. exclusion criteria: * smoking copd * heart diseases * instable cardiovascular diseases

Keywords: copd cognitive training cognitive impairment p300 test moca
a study of incidence of musculoskeletal disorders in children who have received levofloxacin or a standard non-fluoroquinolone therapy for acute bacterial infection

Conditions: Musculoskeletal Diseases

Summary: the purpose of this study is to assess the long-term safety of levofloxacin administered to children as therapy for acute bacterial infection.

this is a prospective (look forward using periodic observations collected predominantly following participant enrollment), long-term, comparative, multicenter, observational study (study in which the investigators/physicians observe the participants and measure their outcomes) to monitor long-term the incidence of musculoskeletal (ms) disorders in children who have received levofloxacin or a standard therapy for acute bacterial infection. approximately 2500 participants who were enrolled in prior phase 3 clinical studies of the use of levofloxacin for the treatment of acute infectious disease will be observed in this study. the study consists of 3 phases: a screening phase; a surveillance phase; and a musculoskeletal disorder follow-up phase. safety evaluations will include assessment of an overall incidence of musculoskeletal disorders that occur during the first 60 days after the first dose of anti-microbial therapy. the specific musculoskeletal disorders to be reported are: tendinopathy (inflammation or rupture of a tendon); arthritis (inflammation of a joint as shown by redness or swelling); arthralgia (pain in a joint); gait abnormality (limping or refusal to walk). other assessments of safety will include interviews using standardized questionnaires to assess the occurrence of musculoskeletal adverse events, physical examinations, and measurement of participants height over the course of 1 year.

Eligibility criteria:
inclusion criteria: * must have taken at least 1 dose of levofloxacin or standard non-fluoroquinolone therapy as part of a phase 3 levofloxacin clinical study (lofbiv-pcap-003, lofbo-otmd-001, lofbo-otmd-002) to treat an acute bacterial infection * parent or legal guardian read and signed the informed consent form exclusion criteria: * participants who do not meet the criteria for enrollment in a prior phase 3 clinical study of levofloxacin or did not take at least one dose of levofloxacin or standard non-fluoroquinolone therapy in 1 of 3 prior phase 3 levofloxacin clinical studies (lofbiv-pcap-003, lofbo-otmd-001, or lofbo-otmd-002)

Keywords: musculoskeletal diseases musculoskeletal disorders childhood disease bone diseases joint diseases levofloxacin quinolones bacterial infections
trial of immediate vs. delayed cord clamping in the preterm neonate

Conditions: PreTerm Birth; PreTerm Neonate

Summary: to determine the short and long term effects of placental transfusion at birth by milking and delayed cord clamping of the umbilical cord in neonates born between 24 weeks 0 days and 34 weeks 0 days weeks' gestation.

this study is intended to be a randomized controlled trial comparing immediate cord clamping which represents the current standard of care at oklahoma university medical center with delayed cord clamping among preterm neonates born between 24 weeks and 34 weeks 0 days weeks' gestation. allocation sequence will be generated by simple randomization using random number table in the stratum 24-28 weeks 6 days and 29 weeks to 34 weeks 0 days weeks' gestation stratum.

Eligibility criteria:
inclusion criteria: * singleton pregnancies * signed consent to participate in the trial exclusion criteria: * major fetal anomaly or known fetal chromosomal abnormalities * multiple gestation * mothers with pregestational and gestational diabetes * refusal to participate in the trial

Keywords: preterm birth preterm neonate high risk pregnancy preterm baby premature baby cord clamping milking the cord
study to evaluate the efficacy and safety of filgotinib in participants with active psoriatic arthritis who have an inadequate response or are intolerant to biologic dmard therapy

Conditions: Psoriatic Arthritis

Summary: the primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the american college of rheumatology 20% improvement (acr20) response in participants with active psoriatic arthritis who have an inadequate response or are intolerant to biologic disease-modifying anti-rheumatic drugs (dmard) therapy.


Eligibility criteria:
key inclusion criteria: * male or female participants who are 18-75 years of age (19-75 years of age at sites in republic of korea, 20-75 years of age at sites in japan and taiwan), on the day of signing initial informed consent * meet classification criteria for psoriatic arthritis (caspar) * have a history consistent with psoriatic arthritis (psa) ≥ 6 months at screening * have active psa defined as ≥ 3 swollen joints (from a 66 swollen joint count \[sjc\]) and ≥ 3 tender joints (from a 68 tender joint count \[tjc\]) at screening and day 1; these may or may not be the same joints at screening and day 1 * must have a documented history or active signs of at least one of the following at screening * plaque psoriasis * nail changes attributed to psoriasis * have had inadequate response (lack of efficacy after ≥ 12 week duration of therapy) or intolerance to at least one and not more than 3 biologic dmards (biodmard) administered for the treatment of psa or psoriasis, as per local guidelines / standard of care * prior to the first dose of study drug on day 1, treatment with biodmard(s) should have been discontinued key exclusion criteria: * prior exposure to a janus kinase (jak) inhibitor \> 2 doses * any active / recent infection * any chronic and / or uncontrolled medical condition that would put the individual at increased risk during study participation or circumstances which may make a individual unlikely or unable to complete or comply with study procedures and requirements, per investigator judgement * any moderately to severely active musculoskeletal or skin disorder other than psa or plaque psoriasis that would interfere with assessment of study parameters, as per judgement of investigator note: prior history of reactive arthritis or axial spondyloarthritis is permitted if there is documentation of change in diagnosis to psa or additional diagnosis of psa * any history of an inflammatory arthropathy with onset before age of 16 years old * active autoimmune disease that would interfere with assessment of study parameters or increase risk to the individual by participating in the study, (e.g. uveitis, inflammatory bowel disease, uncontrolled thyroiditis, systemic vasculitis, transverse myelitis), per judgement of investigator * pregnancy or nursing females * active drug or alcohol abuse, as per judgement of investigator note: other protocol defined inclusion/exclusion criteria may apply.